S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
K Kuo,
D Layton,
A Lal,
H Al-Samkari,
J Bhatia,
P Kosinski,
B Tong,
M Lynch,
K Uhlig,
E Vichinsky
Affiliations
K Kuo
1 Division of Hematology, University of Toronto, Toronto, ON, CANADA
D Layton
2 Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM
A Lal
3 Division of Hematology, UCSF Benioff Children’s Hospital Oakland, Oakland, CA, UNITED STATES
H Al-Samkari
4 Massachusetts General Hospital, Harvard Medical School, Boston, MA, UNITED STATES
J Bhatia
5 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES
P Kosinski
5 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES
B Tong
5 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES
M Lynch
5 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES
K Uhlig
5 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES
E Vichinsky
3 Division of Hematology, UCSF Benioff Children’s Hospital Oakland, Oakland, CA, UNITED STATES
